Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
NCT01701856 · Claudio Gobbi · PHASE4 · terminated · last registry update 2014-01-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Problems to recruit the needed number of patients in the planned time” | – | Registry record, Claudio Gobbi |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IFNAR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-01-08Results posted on the registry: Genzyme, a Sanofi Company, Alemtuzumab 12 mg + Alemtuzumab 24 mg (NCT00548405)
- 2014-11-19Phase 3 first posted: Celgene, Ozanimod + Interferon beta-1a (NCT02294058)
- 2014-11-05Phase 3 first posted: Biogen, dimethyl fumarate + Interferon β-1a (NCT02283853)
- 2014-10-13Phase 3 first posted: Hoffmann-La Roche, Entecavir + Lamivudine (NCT02263079)
- 2014-09-29Results posted on the registry: Merck Sharp & Dohme LLC, Vaniprevir 600 mg b.i.d. + Vaniprevir 300 mg b.i.d. (NCT00943761)
- 2014-09-29Results posted on the registry: Merck Sharp & Dohme LLC, Vaniprevir + Pegylated Interferon (Peg-IFN) (NCT00704405)
- 2014-09-29Results posted on the registry: Merck Sharp & Dohme LLC, Vaniprevir + Pegylated Interferon (peg-IFN) (NCT00880763)
- 2014-09-10Results posted on the registry: Alexion Pharmaceuticals, Inc., ACH-0141625 (Sovaprevir) + ACH-0141625 (Sovaprevir) (NCT01180790)
- 2014-07-28Phase 3 first posted: Hospices Civils de Lyon, Nilotinib (Tasigna ®), capsules of 150 mg + Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®) (NCT02201459)
- 2014-05-07Results posted on the registry: Novartis Pharmaceuticals, RAD001(everolimus) + interferon alfa-2a (NCT00719264)
- 2014-01-28Phase 3 first posted: Celgene, Ozanimod + Ozanimod placebo (NCT02047734)
- 2013-12-27Phase 3 first posted: Gilead Sciences, Sofosbuvir + RBV (NCT02021643)
- 2013-11-04Phase 3 first posted: Teva Branded Pharmaceutical Products R&D, Inc., Laquinimod + Avonex® (NCT01975298)
- 2013-10-28Results posted on the registry: Merck KGaA, Darmstadt, Germany, RNF + RNF (NCT00813709)
- 2013-10-17Results posted on the registry: University of California, San Francisco, Pegylated interferon alfa-2a + Ribavirin (NCT00845676)
- 2013-10-10Results posted on the registry: EMD Serono Research & Development Institute, Inc., Cladribine + Placebo (NCT00725985)
- 2013-09-11Phase 3 first posted: Biogen, BIIB017 + naproxen (NCT01939002)
- 2013-07-04Phase 3 first posted: Novartis Pharmaceuticals, Interferon beta-1a + Fingolimod (NCT01892722)
- 2013-07-01Results posted on the registry: EMD Serono Research & Development Institute, Inc., Cladribine + Placebo (NCT00436826)
- 2013-07-01Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pegylated Interferon/ribavirin (NCT00100659)
- 2013-07-01Phase 3 first posted: TCM Biotech International Corp., Peginterferon alfa-2a + Ribavirin (NCT01890200)
- 2013-06-28Phase 3 first posted: Biocad, Algeron + Pegasys (NCT01889433)
- 2013-06-10Results posted on the registry: Dartmouth-Hitchcock Medical Center, Aldesleukin, + autologous tumor cell vaccine (NCT00085436)
- 2013-05-15Results posted on the registry: National Institutes of Health Clinical Center (CC), Nitazoxanide With Pegylated Interferon And Ribavirin (NCT01185028)
- 2013-05-03Results posted on the registry: EMD Serono, Rebif (NCT01085318)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision